AVITA Medical Inc (RCEL) Stock AnalysisRCELAVITA Medical Inc

AVITA Medical, Inc. is a therapeutic acute wound care company. The Company solutions are designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Its technologies address critical healing needs arising from burns, traumatic injuries, and surgical repairs, through a portfolio and complementary products that support wound bed preparation, definitive closure, and recovery. Its portfolio includes RECELL and two complementary wound care products, PermeaDerm and Cohealyx. Its RECELL technology platform is an autologous cell harvesting technology that enables clinicians to create a suspension of a patient's own skin cells, called Spray-On Skin, at the point of care. Its PermeaDerm is a biosynthetic wound matrix that manufactures, markets, and distributes in the United States, under multi-year agreements with Stedical. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AVITA Medical Inc (RCEL) is a good buy right now due to its current price of $13.04, which is below several analyst price targets, including $15 from BTIG. The stock has shown a strong year-to-date change of +275.79% and a recent improvement in net loss to -$7.66 million in Q2 2026, down from -$10.61 million in Q1 2026, indicating better operational efficiency. However, the main risk is the gross margin decline to 81.7% from 84.7% year-over-year, which could affect profitability going forward.